[1]
|
Emile, J.F., Cohen-Aubart, F., Collin, M., Fraitag, S., Idbaih, A., Abdel-Wahab, O., Rollins, B.J., Donadieu, J. and Haroche, J. (2021) Histiocytosis. The Lancet, 398, 157-170. https://doi.org/10.1016/S0140-6736(21)00311-1
|
[2]
|
Classen, C.F., Minkov, M. and Lehrnbecher, T. (2016) The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses)—Clinical Aspects and Therapeutic Approaches. Klinische Pädiatrie, 228, 294-306. https://doi.org/10.1055/s-0042-109713
|
[3]
|
Singh, P., Shrestha, R. and Yadav, N.K. (2020) Erdheim Chester Disease: A Subtle Quiddity; the First Case Reported from Nepal. Radiology Case Reports, 15, 2080-2084.
https://doi.org/10.1016/j.radcr.2020.08.014
|
[4]
|
Cives, M., Simone, V., Rizzo, F.M., Dicuonzo, F., Cristallo Lacalamita, M., Ingravallo, G., Silvestris, F. and Dammacco, F. (2015) Erdheim-Chester Disease: A Systematic Review. Critical Reviews in Oncology/Hematology, 95, 1-11.
https://doi.org/10.1016/j.critrevonc.2015.02.004
|
[5]
|
Mazor, R.D., Manevich-Mazor, M. and Shoenfeld, Y. (2013) Erdheim-Chester Disease: A Comprehensive Review of the Literature. Orphanet Journal of Rare Diseases, 8, Article No. 137. https://doi.org/10.1186/1750-1172-8-137
|
[6]
|
Arnaud, L., Hervier, B., Néel, A., Hamidou, M.A., Kahn, J.E., Wechsler, B., Pérez-Pastor, G., Blomberg, B., Fuzibet, J.G., Dubourguet, F., Marinho, A., Magnette, C., Noel, V., Pavic, M., Casper, J., Beucher, A.B., Costedoat-Chalumeau, N., Aaron, L., Salvatierra, J., Graux, C., Cacoub, P., Delcey, V., Dechant, C., Bindi, P., Herbaut, C., Graziani, G., Amoura, Z. and Haroche, J. (2011) CNS Involvement and Treatment with Interferon-α Are Independent Prognostic Factors in Erdheim-Chester disease: A Multicenter Survival Analysis of 53 Patients. Blood, 117, 2778-2782.
https://doi.org/10.1182/blood-2010-06-294108
|
[7]
|
Matzumura, M., Arias-Stella, J. and Novak, J.E. (2016) Erdheim-Chester Disease: A Rare Presentation of a Rare Disease. Journal of Investigative Medicine High Impact Case Reports, 4, 1-4. https://doi.org/10.1177/2324709616663233
|
[8]
|
Diamond, E.L., Dagna, L., Hyman, D.M., Cavalli, G., Janku, F., Estrada-Veras, J., Ferrarini, M., Abdel-Wahab, O., Heaney, M.L., Scheel, P.J., Feeley, N.K., Ferrero, E., McClain, K.L., Vaglio, A., Colby, T., Arnaud, L. and Haroche, J. (2014) Consensus Guidelines for the Diagnosis and Clinical Management of Erdheim-Chester Disease. Blood, 124, 483-492. https://doi.org/10.1182/blood-2014-03-561381
|
[9]
|
Jendro, M.C., Zeidler, H., Rosenthal, H., Haller, H. and Schwarz, A. (2004) Improvement of Erdheim-Chester Disease in Two Patients by Sequential Treatment with Vinblastine and Mycophenolate Mofetil. Clinical Rheumatology, 23, 52-56.
https://doi.org/10.1007/s10067-003-0801-7
|
[10]
|
Yano, S., Kobayashi, K., Kato, K., Tokuda, Y., Ikeda, T. and Takeyama, H. (2007) A Case of Erdheim-Chester Disease Effectively Treated by Cyclophosphamide and Prednisolone. Nihon Kokyuki Gakkai Zasshi, 45, 43-48.
|
[11]
|
Gaspar, N., Boudou, P., Haroche, J., Wechsler, B., Van Den Neste, E., Hoang-Xuan K, Amoura, Z., Guillevin, R., Savatovski, J., Azar, N., Piette, J.C. and Leblond, V. (2006) High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Adult Histiocytic Disorders with Central Nervous System Involvement. Haematologica, 91, 1121-1125.
|
[12]
|
Esmaeli, B., Ahmadi, A., Tang, R., Schiffman, J. and Kurzrock, R. (2001) Interferon Therapy for Orbital Infiltration Secondary to Erdheim-Chester Disease. American Journal of Ophthalmology, 132, 945-947.
https://doi.org/10.1016/S0002-9394(01)01141-2
|
[13]
|
Suzuki, H.I., Hosoya, N., Miyagawa, K., Ota, S., Nakashima, H., Makita, N. and Kurokawa, M. (2010) Erdheim-Chester Disease: Multisystem Involvement and Management with Interferon-α. Leukemia Research, 34, e21-e24.
https://doi.org/10.1016/j.leukres.2009.07.026
|
[14]
|
Haroche, J., Amoura, Z., Trad, S.G., Wechsler, B., Cluzel, P., Grenier, P.A. and Piette, J.C. (2006) Variability in the Efficacy of Interferon-α in Erdheim-Chester Disease by Patient and Site of Involvement: Results in Eight Patients. Arthritis & Rheumatology, 54, 3330-3336. https://doi.org/10.1002/art.22165
|
[15]
|
Hervier, B., Arnaud, L., Charlotte, F., Wechsler, B., Piette, J.C., Amoura, Z. and Haroche, J. (2012) Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α. Seminars in Arthritis and Rheumatism, 41, 907-913.
https://doi.org/10.1016/j.semarthrit.2011.11.004
|
[16]
|
Oneal, P.A., Kwitkowski, V., Luo, L., Shen, Y.L., Subramaniam, S., Shord, S., Goldberg, K.B., McKee, A.E., Kaminskas, E., Farrell, A. and Pazdur, R. (2018) FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. The Oncologist, 23, 1520-1524.
https://doi.org/10.1634/theoncologist.2018-0295
|
[17]
|
Cohen Aubart, F., Emile, J.F., Maksud, P., Galanaud, D., Cluzel, P., Benameur, N., Aumaitre, O., Amoura, Z. and Haroche, J. (2018) Efficacy of the MEK Inhibitor Cobimetinib for Wild-Type BRAF Erdheim-Chester Disease. British Journal of Haematology, 180, 150-153. https://doi.org/10.1111/bjh.14284
|
[18]
|
Arnaud, L., Gorochov, G., Charlotte, F., Lvovschi, V., Parizot, C., Larsen, M., Ghillani-Dalbin, P., Hervier, B., Kahn, J.E., Deback, C., Musset, L., Amoura, Z. and Haroche, J. (2011) Systemic Perturbation of Cytokine and Chemokine Networks in Erdheim-Chester Disease: A Single-Center Series of 37 Patients. Blood, 117, 2783-2790.
https://doi.org/10.1182/blood-2010-10-313510
|
[19]
|
Diamond, E.L., Abdel-Wahab, O., Pentsova, E., Borsu, L., Chiu, A., Teruya-Feldstein, J., Hyman, D.M. and Rosenblum, M. (2013) Detection of an NRAS Mutation in Erdheim-Chester Disease. Blood, 122, 1089-1091.
https://doi.org/10.1182/blood-2013-02-482984
|
[20]
|
Girschikofsky, M., Arico, M., Castillo, D., Chu, A., Doberauer, C., Fichter, J., Haroche, J., Kaltsas, G.A., Makras, P., Marzano, A.V., de Menthon, M., Micke, O., Passoni, E., Seegenschmiedt, H.M., Tazi, A. and McClain, K.L. (2013) Management of Adult Patients with Langerhans Cell Histiocytosis: Recommendations from an Expert Panel on Behalf of Euro-Histio-Net. Orphanet Journal of Rare Diseases, 8, Article No. 72. https://doi.org/10.1186/1750-1172-8-72
|
[21]
|
Myra, C., Sloper, L., Tighe, P.J., McIntosh, R.S., Stevens, S.E., Gregson, R.H., Sokal, M., Haynes, A.P. and Powell, R.J. (2004) Treatment of Erdheim-Chester Disease with Cladribine: A Rational Approach. British Journal of Ophthalmology, 88, 844-847.
https://doi.org/10.1136/bjo.2003.035584
|
[22]
|
Haroche, J., Amoura, Z., Charlotte, F., Salvatierra, J., Wechsler, B., Graux, C., Brousse, N. and Piette, J.C. (2008) Imatinib Mesylate for Platelet-Derived Growth Factor Receptor-Beta-Positive Erdheim-Chester Histiocytosis. Blood, 111, 5413-5415.
https://doi.org/10.1182/blood-2008-03-148304
|
[23]
|
Janku, F., Amin, H.M., Yang, D., Garrido-Laguna, I., Trent, J.C. and Kurzrock, R. (2010) Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. Journal of Clinical Oncology, 28, e633-e636. https://doi.org/10.1200/JCO.2010.29.9073
|
[24]
|
Dagna, L., Corti, A., Langheim S., Guglielmi, B., De Cobelli, F., Doglioni, C., Fragasso, G., Sabbadini, M.G. and Ferrarini, M. (2012) Tumor Necrosis Factor α as a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients with Infliximab. Journal of Clinical Oncology, 30, e286-e290.
https://doi.org/10.1200/JCO.2012.41.9911
|